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Infection of rhesus macaques with attenuated SIVmac is, at present, the only strategy which confers significant protection
from challenge with wild-type SIVmac grown in monkey PBMC. However, initial results suggest that the protective mechanism
does not develop until late after ‘‘vaccination’’ (approx 10 months). As part of a European study using the C8 variant of
SIVmac251-32H (containing an in-frame 12-bp deletion in the nef gene), we wished to determine (a) if protection could be
achieved against challenge with a ‘‘swarm’’ of SIVmac251-32H produced in monkey cells and (b) if protection could be
demonstrated after a short period of infection with the attenuated virus. Eight Indian rhesus macaques were infected with
C8 and four were challenged after 10 weeks with 50 MID50 of an uncloned stock of SIVmac251-32H grown in rhesus cells,
and the other four were challenged after 20 weeks. Four animals served as naive controls. Three of the four monkeys
challenged at 10 weeks and three of those challenged at 20 weeks were protected from productive superinfection. From
one monkey in each group it was, however, possible to demonstrate the presence of the wild-type provirus in monkey
PBMC by diagnostic PCR and anamnestic immune response. There was no apparent correlation between the levels of
binding or neutralizing antibodies on the day of challenge and subsequent protection. Approximately 1 year after infection
with the attenuated virus all monkeys were rechallenged with the heterologous SIVsm strain, first with 10–20 MID50 and
then with 1000 MID50 . Although not all of the SIVsm-inoculated naive controls became productively infected, PCR analysis
failed to reveal any evidence for infection of the ‘‘immunized’’ monkeys. q 1996 Academic Press, Inc.
INTRODUCTION D3 can grow to high titers and cause AIDS in neonatal
macaques has intensified opposition to the use of a live
By far the most successful forms of vaccines tested in
attenuated retroviral vaccine. Most researchers working
the SIVmac/rhesus animal model for AIDS have been
with attenuated SIVmac vaccines therefore view the vi-
those based on a live attenuated form of SIVmac. Daniel
ruses as tools to help identify the mechanisms of protec-
et al. (1992) first demonstrated that prior infection with a
tion in the hope that it might be possible to artificially
clone of SIVmac containing large deletions in the nef
stimulate such mechanisms without using replication-
gene, a virus highly attenuated in its replicative capacity
competent SIV.
in vivo (Kestler et al., 1991), would fully protect from sub-
One of the difficulties in understanding the way in
sequent challenge with the pathogenic wild-type virus.
which attenuated SIV imparts protection has been the
This is in stark contrast to the weak or nonexistent pro-
time needed after infection with the vaccine strain for the
tection afforded by other vaccines such as those based state of immunity to develop. In the original experiment
on inactivated virus, purified virus proteins, or recombi- animals were challenged over a year after ‘‘vaccination’’
nant vectors (Dormont et al., 1995; Schultz and Stott, and Wyand et al. (1994) have shown that animals infected
1994). with SIVmac239 D3 are not protected after 8 weeks, par-Despite the efficacy of live attenuated SIVmac vac- tially protected after 20 weeks, and fully protected after
cines it is unlikely that a live attenuated HIV-1 would be 79 weeks. In contrast it is known that the antiviral im-
used in the near future as a human vaccine because of mune response following infection with SIVmac develops
understandable concerns and uncertainties about safety. rapidly, with neutralizing antibodies detectable after only
Further deletions in the SIVmac vpr and NRE genes by 2–3 weeks and virus-specific CTL even earlier (Beer et
Desrosiers and colleagues (Wyand et al., 1994) to yield al., 1995; Yasutomi et al., 1993).
the highly attenuated SIVmac239 D3 showed that it is Rud et al. (1994) recently described the molecular clon-
possible to produce an effective vaccine strain with virtu- ing and characterization of a naturally occurring variant
ally no chance of reversion. However, the recent demon- (C8) of SIVmac251-32H whose major difference from the
stration by Baba et al. (1995) that this same SIVmac239 full-length J5 clone is a four-amino-acid deletion in the
Nef protein. A European Community Concerted Action
project involving eight institutes was subsequently de-1 To whom correspondence and reprint requests should be ad-
dressed. signed to examine the breadth of protection stimulated
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by this attenuated C8 vaccine. As part of this project we staining (Norley et al., 1993). Negative cultures were con-
firmed by a further test after 56 days in culture.infected eight monkeys with SIVmac32H C8 and challenged
at different times with an uncloned pathogenic ‘‘swarm’’ The number of circulating PBMC containing replica-
tion-competent virus was determined by limiting dilutionof SIVmac251-32H . We demonstrate here that protection
was near complete after only 10 and 20 weeks, respec- coculture. Different numbers of PBMC (101 to 106 cells)
were cocultivated with 1 1 106 C8166 cells in 24-welltively. Furthermore, upon rechallenge 1 year later the
monkeys were found to resist infection with the heterolo- plates in triplicate. After 28 days the cultures were ana-
lyzed for the presence of SIVmac infection by immuno-gous SIVsm isolate.
peroxidase staining. The results of the titration were used
to calculate the number of infected cells per millionMATERIALS AND METHODS
PBMC with a Poisson distribution fitting model.
Rhesus monkeys Measurement of plasma p27 antigenemia was per-
formed using the commercial SIV core antigen assay
The 17 rhesus macaques used in this study were of (Coulter Electronics, Luton, UK) according to manufactur-
Indian origin and were housed and handled at the Paul- er’s protocol. Virus was pelleted from 1.7 ml plasma (1:2
Ehrlich-Institute under conditions complying with the rel- diluted) by centrifugation at 12,000 rpm for 2 hr and the
evant European guidelines. The animals had been pellet was resuspended in 200 ml PBS before use in the
screened for SIV, STLV, and SRV before entering the assay.
study. Following inoculation of SIVmac, the monkeys
were monitored daily for general clinical status. Body ELISA
weight, temperature, and lymph node size, plus hemato-
Titers of virus-specific antibodies were determined us-logical and other parameters were investigated at the
ing standard ELISA protocols. Sera were titrated ontime of each bleeding. Percentages of CD4- and CD8-
ELISA plates coated with either detergent-disrupted su-positive lymphocytes were determined by FACS analysis
crose gradient-purified whole SIVmac or a lysate of cells(Facstar plus; Becton–Dickinson, Heidelberg, Germany)
infected with a SIVmac env–vaccinia recombinant virusof gated lymphocyte populations after indirect staining
(kindly provided through Program EVA by Erling Rud,with Leu 3a (Becton–Dickinson) or OKT 8 (Ortho Diag-
Health Canada). The antibody titer of each serum wasnostic Systems) monoclonal antibody and fluorescein-
calculated by extrapolating the line of best fit in the linearconjugated AffiniPure F(ab*)2 fragment goat anti-mouse
area of the dilution curve and determining the dilution atIgG (Dianova) using standard protocols.
which this line intersected the cutoff OD (0.2).
Cells and viruses
Neutralization test
C8166 cells were obtained from the MRC AIDS Re- The neutralization test was performed as described
agent Project (UK) and cultured in RPMI 1640 supple- previously (DeVries et al., 1994). Briefly, 10 ml of virus
mented with 10% FCS, 2 mM L-glutamine, 100 mg neomy- stock diluted to give 20 infectious particles per 10 ml was
cin, 100 U penicillin, and 100 mg streptomycin per millili- mixed by shaking in U-well microtiter plates with 10 ml
ter. SIVmac32H C8 was initially cloned and characterized serum at different dilutions (in quadruplicate). After 30-
by Rud et al. (1994) and the immunizing virus stock was min incubation (377, 5% CO2 , 98% humidity) 200 ml of
prepared and kindly donated through Program EVA by C8166 cell suspension (104 cells/ml) was added to each
Martin Cranage, CAMR, UK. The cell-free SIVmac32H well. Plates were then incubated for 7 days, after which
stock 5 swarm challenge virus stock was prepared from cells were transferred to poly-L-lysine-coated F-96 micro-
SIVmac32H-infected rhesus PBMC and titrated in rhesus titer plates before methanol fixing and SIV-specific immu-
macaques at the Paul-Ehrlich-Institute. The SIVsm chal- noperoxidase staining. The neutralizing antibody titer
lenge virus stock was prepared from cynomolgus ma- was calculated from the number of wells containing no
caque peripheral blood mononuclear cells (PBMC), ti- infected cells as the ‘‘neutralizing dose 50% endpoint’’
trated in cynomologus macaques, and kindly donated by (ND50) using a computerized adaptation of the Spear-
Per Putkonen, SIIDC, Sweden. mann–Ka¨rber method.
Virus reisolation and measurement of virus load Diagnostic PCR
Diagnostic PCR to distinguish between Nef-deficientPBMC were separated from whole citrated blood by
Ficoll–diatrizoate (Histopaque; Sigma, Deisenhofen, SIVmac32H C8 and full-length Nef (wild-type) challenge vi-
rus was performed using an adaptation of a nested PCRGermany) density gradient centrifugation, and 1.5 1 106
PBMC from each monkey were cocultivated with 5 1 106 protocol developed by Neil Almond (NIBSC, UK). PBMC
(105) were lysed in sterile distilled water and digestedC8166 cells. After 28 days the cultures were analyzed for
the presence of SIVmac infection by immunoperoxidase with 0.005 mg/ml proteinase K in 700 nM sodium dodecyl
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sulfate for 4 hr at 507 before inactivating the proteinase SIVmac antigen in ELISA between 2 and 4 weeks after
infection, generally rising steadily thereafter to plateauK for 10 min at 957. Nested PCR was used to amplify a
480/492-bp product spanning the site of the nef deletion. at titers of 1000–100,000 (Fig. 1). The development of
antibodies able to bind SIVmac recombinant gp140 inPCR was performed in a volume of 100 ml containing 10
mM Tris–HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2 , 0.001% ELISA followed similar patterns. Similarly, infection with
SIVmac32H C8 resulted in the rapid development of anti-gelatine, 200 mM each dNTP, and 500 nM each primer.
Amplification was started with an initial denaturation step bodies able to neutralize SIVmac in vitro, with titers of
240 ND50 being detectable as early as 4 weeks p.i. (dataof 4 min at 947 followed by 40 cycles each of 30 sec at
947, 1 min at 557, 1 min at 727, and finally 10 min at 727. not shown). The humoral immune response to SIV-
mac32H C8 infection was therefore generally similar inFor the initial 40 cycles primers 5*-GAC CTA CCT ACA
ATA TGG G-3* (9044–9061) and 5*-TCA GCG AGT TTC terms of kinetics and magnitude to that seen following
infection with the full-length wild-type virus (Beer et al.,CTT CTT CTT GT-3* (9866 –9847) were used. Ten percent
of the first-round PCR product was then further amplified 1995; Fig. 1).
by 40 cycles using primers 5*-GAA TAC TCC ATG GAG
AAA CC-3* (9272–9292) and 5*-GGG TAT CTA ACA TAT Response to challenge
GCC TC-3* (9763–9744). The final PCR products were
precipitated by 2 volumes ethanol in 0.3 M sodium ace- At 10 or 20 weeks after infection with the Nef-deficient
variant of SIVmac, all animals, plus four control monkeys,tate, washed twice, and resolved in Tris–EDTA before
digesting 10% with RsaI. The digestion products were were infected intravenously with 50 MID50 of the patho-
genic SIVmac251 32H swarm (stock 5; Norley et al., 1995).analyzed on a 2.2% agarose gel which allowed SIV-
mac32H C8-specific sequences (378 and 102 bp) to be dis- All four control animals were infected, yielding virus at
each bleeding during the 10 weeks after challenge andtinguished from wild-type-specific sequences (256, 134,
and 102 bp). a positive PCR signal at each time point (Tables 1 and
2). In addition, each control animal developed a rapidTo detect SIVsm-specific sequences a seminested
PCR was performed using conditions similar to those antibody response (anti-SIVmac, anti-gp140, and neu-
tralizing antibodies; Fig. 1).described above. Primers 5*-CCT ACC TAC AAT ATG
GGT GGA G-3* (9063 for C8, 9065 for SM virus) and 5*- Of the four C8-infected monkeys challenged at 10
weeks, three showed no evidence of challenge virus rep-GTT TCC TTC TTG TCA GCC AT-3* (9859 for C8, 9860
for SIVsm) were used in the initial 40 cycles, and for the lication whatsoever, remaining reisolation negative (with
the exception of one time point) and only sporadicallysecond round the upstream primer of the initial PCR plus
primer 5*-CTC TTG CGG TTA GCC TTC CT-3* (9828 for PCR positive for the C8 virus. No trace of full-length nef-
DNA could be detected using the diagnostic PCR (TableC8, 9830 for SIVsm) were used. Digestion with RsaI pro-
duced fragments specific for SIVmac32H C8 , wild type, and 2). However, one animal, rhesus 68, became sporadically
reisolation positive after challenge and showed a sec-SIVsm, respectively.
ond, higher peak of virus load at 6 week postchallenge.
At the time of this peak it was possible to demonstrateRESULTS
a weak ‘‘wild-type’’ pattern in the diagnostic PCR (Table
Infection with Nef-deficient SIVmac C8
1A) and the animal showed a strong transient inversion
of the CD4/CD8 ratio (data not shown). The mixed PCRAs shown in Tables 1A and 1B, it was possible to
reisolate virus from all monkeys 2 weeks after injection pattern was observed in each sample between Weeks
12 and 32 after challenge when the full-length nef patternwith 10,000 MID50 SIVmac32H C8 . With the exception of
rhesus 68, which showed a maximum of 331 infected became dominant. Additionally, in contrast to the other
three animals, rhesus 68 showed a clear anamnesticPBMC per million, the virus load in these animals peaked
at between 3 and 33 infected cells. This is in stark con- antibody response following challenge to both whole SIV-
mac antigen and rgp140 (Fig. 1).trast to the control animals infected with 50 MID50 of
wild-type swarm SIVmac32H whose virus loads peaked at A similar result was obtained with the animals chal-
lenged 20 weeks after SIVmac32H C8 infection. Two animalsbetween 558 and 10,460 infected cells per million. The
level of plasma antigenemia in the C8-infected rhesus showed no trace of the challenge virus at all, whereas in
rhesus 74 and 79 it was possible to detect a faint wild-was at no time high enough to allow detection using the
commercial p27 antigen capture assay, whereas control type pattern in addition to the strong C8 pattern using the
diagnostic PCR at Weeks 2 and 6 after challenge, respec-monkeys infected with the wild-type virus were positive
in this assay at 2 weeks after infection (data not shown). tively. However, in comparison to rhesus 68 (from the 10-
week group) the level of wild-type virus replication in theseMonkeys infected with the attenuated virus became PCR
positive at 2–3 weeks p.i., and remained positive at every two animals was apparently much reduced. Attempts to
reisolate virus from PBMC succeeded at only one timebleed until the time of challenge.
Each animal developed antibodies able to bind whole point each after challenge and there was no second peak
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TABLE 1A
Virus Reisolation and Cell-Associated Virus Load in Rhesus Monkeys Challenged 10 Weeks after C8 Infection
Note. The shaded area indicates postchallenge samples.
a Reisolation of SIVmac from PBMC by C8166 coculture. The number in parentheses indicates the cell-associated virus
load in positive cells per million PBMC. The minus (0) sign indicates that the samples were reisolation negative.
b ND, not done.
c Monkey euthanized after development of AIDS symptoms.
of virus load detectable. In addition all subsequent PCR able. In contrast, one of the control monkeys (Rh 69)
experienced a rise in virus load 20 weeks after infectionanalyses were either negative or positive for the C8 virus
only. In terms of antibody responses only rhesus 74 ap- with a concomitant drop in CD4/ cell count. By 30 weeks
p.i. the animal had begun to display signs of AIDS devel-peared to have undergone productive infection of sufficient
magnitude to stimulate an anamnestic immune response. opment (weight loss, apathy, diarrhea) and was euthan-
ized.Rhesus 79, which yielded a ‘‘mixed’’ PCR pattern in only
one of six PCR samples taken at 2 weeks postchallenge
Rechallenge with SIVsmand which had no anamnestic immune response, is consid-
ered to have not been productively infected. Comparison Having shown that the majority of animals infected
of the titers of antibodies binding SIVmac antigen or recom- with the Nef-deficient C8 variant of SIVmac were pro-
binant gp140 or able to neutralize SIVmac in sera taken on tected from challenge with the pathogenic, homologous
the day of challenge failed to reveal any correlation be- swarm virus after only 10 and 20 weeks, we were inter-
tween these immune responses and protection from chal- ested to examine the breadth of protection afforded by
lenge (Table 3). such a vaccine. Approximately 1 year after C8 infection
One year after infection with the C8 Nef-deficient vari- all surviving animals (including the wild-type infected
ant of SIVmac none of the eight rhesus monkeys (includ- controls) were rechallenged with SIVsm. This challenge
ing those with evidence of challenge virus replication) virus stock had been previously titrated intravenously
showed any signs of disease development. The numbers and intrarectally in cynomologus macaques. Assuming
of circulating CD4/ lymphocytes remained stable (data that the titer in rhesus macaques would be similar (as
had been shown for other virus stocks including the SIV-not shown) and virus loads remained low to undetect-
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TABLE 1B
Virus Reisolation and Cell-Associated Virus Load in Rhesus Monkeys Challenged 20 Weeks after C8 Infection
Note. The shaded area indicates postchallenge samples.
a Reisolation of SIVmac from PBMC by C8166 coculture. The number in parentheses indicates the cell-associated virus
load in positive cells per million PBMC. The minus (0) sign indicates that the samples were reisolation negative.
b ND, not done.
mac251 32H 11/88 challenge virus), we challenged half of the 11 previously SIVmac32H C8- or wild-type-infected mon-
keys. However, even with 1000 cynomolgus infectiousanimals with 10 cynomolgus infectious doses intrarec-
tally and half with 20 cynomolgus infectious doses intra- doses 1 of the 4 control animals remained reisolation,
PCR, and antibody negative. The 1 fully naive controlvenously. Two naive controls were included for each
route of inoculation. After challenge it was not possible animal experienced virus loads and seroconversion typi-
cal of an acute infection. The virus loads in the otherby diagnostic PCR to demonstrate replication of SIVsm
in any of the preinfected animals although only one of two infected animals (which had not been productively
infected after the previous challenge with 20 cynomolgusthe four naive control monkeys became productively in-
fected. The titer of the SIVsm challenge stock therefore infectious doses) was in comparison 2–3 orders of mag-
nitude lower (Table 4).appeared to be much lower in rhesus macaques.
Eight weeks after the first SIVsm exposure we chal-
lenged the animals once more, this time with 1000 cyno- DISCUSSION
molgus infectious doses of SIVsm intravenously. As con-
trols the 3 exposed but uninfected rhesus from the first The original studies by Desrosiers group (Daniel et al.,
1992) using a Nef-deleted mutant of SIVmac as a vaccineSIVsm challenge were used plus one further naive con-
trol. Following challenge it was again not possible by demonstrated the potency of live attenuated viruses in
protecting against subsequent infection with the patho-any criteria to demonstrate SIVsm infection of any of the
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FIG. 1. Development of binding antibodies specific for whole SIVmac antigen (j) and recombinant gp140 (h) before (white) and after (gray)
challenge with wild-type SIVmac. (A) Monkeys challenged 10 weeks after infection with SIVmac32H C8 . (B) Monkeys challenged 20 weeks after
infection with SIVmac32H C8 .
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TABLE 2
Diagnostic PCR Analysis of Proviral DNA in PBMC of C8-Infected and Challenged Rhesus Macaques
Note. The shaded area represents probes taken after challenge.
a Weeks post infection with SIVmac C8.
b Rhesus number.
c Result of diagnostic PCR analysis: Neg., PCR negative; C8, banding pattern consistant with C8 provirus sequence; wt, banding pattern consistant
with wild-type (challenge) provirus sequence; C8(wt), mixed banding pattern, predominantly C8-like plus weak wild-type pattern.
d This sample yielded a mixed pattern in only one from six replicates.
genic wild-type virus. Further investigations (Wyand et cine in these studies (SIVmac32H C8) and the full-length
SIVmac J5 molecular clone is a four-amino-acid deletional., 1994) using the SIVmac D3 virus containing deletions
in vpr and NRE as well as nef extended these observa- in the Nef protein. This deletion has been shown to be
sufficient to impart an attenuated phenotype in vivo (Al-tions but clearly demonstrated that a long period of infec-
tion (20 weeks) with the attenuated virus was neces- mond et al., 1995; Rud et al., 1994) and animals infected
with C8 were shown to be protected from subsequentsary to impart a state of protective immunity. This has
been, and remains, one of the central puzzles sur- challenge with the pathogenic full-length molecular clone
J5. In the studies presented here we wished to determinerounding the use of live attenuated virus vaccines in the
SIV model. It has clearly been demonstrated that the full whether this virus could also protect against challenge
with an uncloned swarm of SIVmac and whether therepertoire of the immune response to SIVmac develops
within the first few weeks after infection (Beer et al., 1995; period of infection before challenge could be reduced.
Inoculation of rhesus macaques with the C8 Nef-deletionYasutomi et al., 1993) and as yet it has not been possible
to identify the mechanism of protection involved. variant resulted, as expected, in an attenuated course of
infection compared to that seen following infection withThe major difference between the virus used as a vac-
AID VY 7889 / 6a15$$$503 04-02-96 18:26:46 vira AP: Virology
202 NORLEY ET AL.
TABLE 3
Antibody Titers on the Day of Challenge
the full-length challenge virus swarm. The peak number of showed no biological evidence for challenge virus repli-
cation and for the purposes of this discussion is consid-infected PBMC in circulation as measured by limiting dilu-
tion cocultures was 1–2 orders of magnitude lower and ered protected.
In contrast to previous studies using attenuated SIV-the virus became increasingly difficult to reisolate after 8
weeks. The humoral immune response, however, was simi- mac vaccines where long periods of ‘‘immunization’’ were
used before protection could be demonstrated, the C8lar in rapidity and magnitude to that seen following infection
with the wild-type virus (Table 1, Fig. 1). variant used here seems able to protect three of four
monkeys from challenge with a pathogenic swarm afterFour of the C8-infected rhesus macaques were inocu-
lated intravenously at 10 weeks p.i. with 50 MID50 of the only 10 or 20 weeks. Analysis of the immune responses
at the day of challenge (Table 3) failed to reveal anypathogenic SIVmac32H swarm and the second group of
four monkeys at 20 weeks p.i. Three of the four animals correlation between the levels of binding or neutralizing
antibodies and protection. Others (F. Gotch, personalchallenged at 10 weeks showed no evidence whatsoever
of challenge virus replication: they remained reisolation communication) have shown the stimulation of Nef-spe-
cific CTL in response to infection with SIVmac32H C8 butnegative (except one time point), yielded only a C8 pat-
tern in the diagnostic PCR, and did not undergo an anam- no correlation with subsequent protection could so far be
demonstrated. As such the mechanism of the protectionnestic antibody response. One animal, Rh 68, however,
had a second peak in virus load 6 weeks after challenge given by attenuated SIV vaccines remains unknown. In-
deed, there is no convincing evidence that the protectionand a clear boost in the titers of antibodies specific for
whole SIVmac antigen or recombinant gp140. In addition, is mediated by a specific antiviral immune response at
all. One pattern which is emerging from studies such asthis animal yielded a mixed pattern in the diagnostic PCR
until 42 weeks after challenge when the pattern became these is that the degree of protection is linked to the
replicative capacity in vivo of the immunizing virus. Theexclusively wild type. By the criteria used in this study,
three of four C8-infected monkeys were therefore fully original SIVmac239Dnef from Desrosiers’ group is se-
verely attenuated and the SIVmac239 D3 even more so.protected after 10 weeks from challenge with the full-
length pathogenic swarm of SIVmac. Indeed, Wyand et al. (1994) showed that a single deletion
Dnef vaccine based on the macrophage-tropic strainTwo of the four rhesus challenged after 20 weeks of
C8 infection also showed no evidence at all of challenge SIVmac316 is even more attenuated than the triple-dele-
tion SIVmac239 D3 and has a correspondingly reducedvirus replication. Two, however (Rh 79 and Rh 74), gave
a mixed signal in the diagnostic PCR at 2 and 6 weeks protective capacity. The C8 virus used here, although
showing the attenuated phenotype in vivo, has only apostchallenge, respectively. In addition, Rh 74 underwent
an anamnestic immune response, a clear indication of a four-amino-acid deletion in the Nef protein and may in-
deed retain at least part of it’s Nef function.limited degree of virus replication at least. Rh 79, how-
ever, which was positive for the challenge virus at one The idea that protection is linked to the replication
capacity of the vaccine virus is supported by the observa-time point in only one of six replicate PCR probes,
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TABLE 4
Outcome of the Rechallenge with SIVsm
a All surviving monkeys from the initial study were rechallenged at 1 year postinfection with 10 MID50 intrarectally or 20
MID50 intravenously (titers determined in cynomolgus macaques).
b All C8- and wt-infected monkeys, the uninfected controls from the first SIVsm challenge, plus one naive animal (Rh 203)
were rechallenged 8 weeks later with 1000 MID50 SIVsm intravenously.
c IR, intrarectal challenge; IV, intravenous challenge.
d Results of attempts to reisolate virus from PBMC in coculture at 3 weeks postchallenge. The number in parentheses
indicates the cell-associated virus load in positive cells per million PBMC.
e Result of diagnostic PCR analysis: Neg., PCR negative; C8, banding pattern consistant with C8 provirus sequence; wt,
banding pattern consistant with wild-type (challenge) provirus sequence; SIVsm, banding pattern consistant with SIVsm
provirus sequence.
tion that Dnef mutants based on the SIVmac BK28 clone debatable. In this study, SIVmac32H C8 was shown to be
a ‘‘better vaccine’’ than the SIVmac239 D3 developed(which is itself relatively nonpathogenic) have a reduced
protective capacity (Kieny et al., 1993). In addition, HIV- by Desrosiers’ group. However, C8 has been shown to
be quite capable of filling in the four-amino-acid dele-1 Dnef and D3 mutants tested for their vaccine effect in
chimpanzees failed to protect against wild-type chal- tion and reverting to a full-length, pathogenic virus
(Whatmore et al., 1995) — it is by no means a safe formlenge (Desrosiers et al., 1995). Although the latter result
is disappointing, it is known that HIV-1 itself is generally of vaccine. Finding the optimal balance between safety
and efficacy may prove difficult or even impossible.attenuated in chimpanzees compared to humans and,
indeed, preinfection with one strain of full-length HIV-1 Although our attempts to infect the protected mon-
keys in our study with the relatively distantly relateddoes not appear to prevent superinfection by another,
closely related strain (Fultz et al., 1995). SIVsm strain failed to show any sign of SIVsm replica-
tion, interpretation is hindered by the failure of theIf protection requires that a relatively high degree of
vaccine virus replication takes place in the vaccinee challenge virus to infect all controls. In vivo titrations of
other challenge stocks in both rhesus and cynomolgusthe potential for using attenuated HIV-1 vaccines is
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macaques have yielded similar titers for the two spe- REFERENCES
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